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Introduction 
Atherosclerosis  
 Atherosclerosis is a chronic vascular inflammatory disease characterized by the formation 
of lesions in the arterial wall of medium to large arteries.  These raised lesions cause narrowing 
of the vessel and are often calcified.  Atherosclerotic lesions present serious health risks and 
investigation into both their causes and consequences is ongoing.  Lesion formation begins when 
monocytes, a type of white blood cell, adhere to areas of vascular injury.  Vascular injury occurs 
when the inner endothelial layer of the vessel is damaged and broken by turbulent blood flow. 
The monocytes migrate into the intima, the area between the endothelium and smooth muscle 
cells of the vascular wall. There the monocytes proliferate and differentiate into macrophages.  
The primary function of these macrophages is to ingest atherogenic lipoproteins that have 
inadvertently entered the vessel wall.  These lipoproteins enter through the same injured areas 
that the monocytes adhere to and include low density lipoproteins (LDL), carrier of the “bad 
cholesterol.”  LDL is oxidized when it enters the vascular wall to produce oxidized LDL 
(oxLDL). OxLDL causes damage to the cells in vessel walls, so the macrophages digest these 
molecules to remove the agents and prevent damage.  Ingestion of oxLDL induces macrophage 
apoptosis, or programmed cell death.   
The buildup of cellular debris from apoptosis and other contaminants in the vessel wall 
forms the atherosclerotic lesion.  Despite this, macrophage apoptosis has been shown to play a 
protective role in the initial stages of lesion formation [1].  Clearance of apoptotic cells initially 
slows the growth of the plaque by removing cell debris and some of the dangerous lipoproteins.  
Advanced lesion macrophage apoptosis is a pro-atherosclerotic process.  In later stages, 
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apoptosis contributes to the instability and rupture of plaques [2].  Ruptured plaques can cause a 
multitude of issues including causing blockages and exposing thrombogenic material within the 
plaque that leads to blood clotting.  Very advanced atherosclerotic lesions are also often calcified 
for reasons that remain unclear.  Calcification of coronary arteries is a well-established risk 
factor and a predictor of future cardiac events [3, 4], and the measure of calcified lesions is 
independently associated with cardiovascular disease events and total mortality [5,6].  The 
process of lesion calcification has been shown to be similar to mechanisms of embryonic bone 
formation [7-9], and is suspected to be at least partially controlled by the type-2 cannabinoid 
receptor (CB2). 
Type-2 Cannabinoid Receptor  
Two distinct types of cannabinoid receptors function in mammals.  The first, the CB1 
receptor, is most prevalent in the central nervous system where it controls the neurological and 
psychotropic effects of cannabinoids [10].   CB2, primarily expressed in immune cells, exerts the 
immunosuppressive effects of cannabinoids [11, 12].  The CB2 receptor has been shown to 
modulate several macrophage processes associated with atherosclerosis including the 
susceptibility to oxLDL-induced apoptosis [13].   While CB2 receptor deficiency did not affect 
the size of lesions in mice, it did increase macrophage accumulation and infiltration of smooth 
muscle cells as well as alter the extracellular matrix composition of the lesions [11].  It is 
possible that CB2 alters the extracellular matrix in part by controlling the formation of 
osteoclasts and osteoblasts in the lesion. 
 The osteoclast is a specialized cell type derived from a monocyte-macrophage lineage 
that functions to resorb and degrade bone [14].  Fibroblast-like osteoblasts are the primary 
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controllers of bone formation, opposing the osteoclasts [15].  Both CB1 and CB2 receptors have 
been found in the skeleton in proximity to these bone cells.  CB1 is primarily expressed at neural 
junctions near osteoblasts and preosteoblasts, cells destined to become osteoblasts, [16-18] while 
CB2 has been found within osteoblasts and their committed precursors.  CB2, as mentioned 
above, affects bone formation, and potentially lesion calcification, as CB2-deficient mice show 
bone density abnormalities and altered lesion characteristics.  In the first two to three months of 
life CB2-null mice, grow normally and display a normal bone mass, but later they display a 
drastically enhanced age-related bone loss [17].  CB2-deficient mice have greatly increased 
osteoclast formation and a much higher rate of bone loss.  Thus, CB2 probably functions as a 
repressor for osteoclastogenesis during bone remodeling processes. 
Atherosclerotic Lesion Calcification 
 Lesion calcification is a cell driven process that appears to be similar to bone formation 
with osteoclast-like cells and osteoblast-like cells being extremely important markers in 
advanced or calcified atherosclerotic lesions.  The differentiation of cells into osteoclasts is 
controlled primarily by levels of osteoprotegerin (OPG) and receptor activator of nuclear factor 
kappa B ligand (RANKL) [19].  OPG acts as a decoy receptor for RANKL, preventing binding 
to its receptor (RANK) and differentiation of cells into osteoclasts.  RANKL and its receptor are 
both present in osteoclasts and their precursors [19] and are expressed in the osteoclast-like cells 
in advanced atherosclerotic lesions.  RANKL can induce osteoclastogenesis in 
monocyte/macrophage cell lines in vitro [20].  Tartrate-resistant acid phosphatase (TRAP) is 
produced by osteoclasts, but not macrophage lineage precursors, so TRAP expression and 
activity are markers of osteoclastogenesis.  Osteoclasts or osteoclast-like cells have been 
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detected in advanced lesions using TRAP as marker [21]. High levels of TRAP have been found 
near RANKL-positive lesion areas [21].   
RANKL is produced by smooth muscle cells in the vascular wall in response to oxidative 
stress from molecules like oxLDL. However, RANKL does not cause vascular smooth muscle 
cell (VSMC) calcification and is not required for oxidative stress-induced hardening.  Rather, 
oxidative stress-stimulated smooth muscle cells promote migration of macrophages into a lesion 
in connection with RANKL.  Instead of contributing directly to calcification of smooth muscle 
cells, RANKL recruits macrophages which then differentiate into osteoclast-like cells in the 
lesions based on OPG/RANKL levels [21].  Osteoclastic cells are produced in atherosclerotic 
lesions when RANKL from modified smooth muscle cells activates the initiation of 
osteoclastogenesis. The master osteogenic transcription factor Runx2 is an essential regulator in 
this pathway producing RANKL because it directly binds to the promoter and induces the 
expression of RANKL in VMSCs [21].   
Oxidative stress of vascular smooth muscle cells can also cause osteoblastogenesis from 
VMSC precursors.  In vitro studies have shown that hydrogen peroxide (H2O2) can induce 
VMSC calcification [22].  Vascular calcification of arteries reflects osteochondrogenic 
transformation of vascular smooth muscle cells, which is associated with increased expression of 
growth factors, matrix proteins and other bone-related markers [23-25].  Therefore, osteoblasts 
are also an important marker in advanced atherosclerotic lesions.  Osteoblastic activity can be 
detected both by calcium deposition, since osteoblasts are calcium-depositing cells, and by 
alkaline phosphatase (ALP) activity.  ALP can be detected using a similar assay to the one used 
to determine TRAP activity in osteoclasts and is a good indicator for osteoblastogenesis in vitro 
because osteoblasts and their committed precursors produce it in significant quantities while 
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smooth muscle cells do not.  Lesion calcification occurs when osteoblasts outnumber osteoclasts 
causing the deposition rate to exceed the rate of calcium uptake. 
Justification and Objective 
The overall aim of this research is to determine CB2-dependent effects on atherosclerotic lesions.  
Previous studies indicate that CB2 receptors play an integral role in the activation of 
osteogenesis by modulating the expression of osteogenic genes during bone remodeling [20, 21] 
and work from our laboratory recently demonstrated that CB2 receptors modulate cellular and 
molecular processes within atherosclerotic lesions in a murine model of atherosclerosis [11].  
This suggests that CB2 receptors may play an integral role in the calcification of atherosclerotic 
lesions.  Though previous studies have examined the CB2-mediated effects on osteogenesis in 
relation to bone formation [16], there has been no investigation of the effects of CB2-signaling 
on lesion calcification.  By increasing our understanding of the role CB2 performs in lesion 
calcification, it may be possible to design treatments, which effectively target CB2 and slow the 
calcification of atherosclerotic lesions. We hypothesize that CB2 modulates osteogenic processes 
within lesions to reduce osteoclastogenesis and activate osteoblastogenesis, thus promoting 
lesion calcification.  To begin to test this hypothesis, we investigated the effects of CB2 
signaling on murine osteogenic cell lines in vitro.  The effects of CB2 agonists and antagonists 
on osteoclastogenesis in a murine monocyte/macrophage cell line and osteoblastogenesis in a 
murine smooth muscle cell line were studied.  
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Materials and Methods 
Cell Culture and Reagents 
 RAW 264.7 cells (transformed murine monocytic cell line) and MOVAS-1 cells 
(transformed murine vascular smooth muscle cell line) were purchased from the American type 
culture collection (ATCC, VA, USA). RAW 264.7 cells were cultured to confluence in 10 cm
 
plates in Dulbecco’s Modified Eagle Medium (DMEM, Invitrogen, CA, USA) containing 4.5 g/L 
D-Glucose, L-glutamine, and 110 mg/L sodium pyruvate, with the addition of 10% heat-
inactivated fetal bovine serum (FBS) and 1% penicillin-streptomycin (10,000 U/mL; Invitrogen, 
USA) [26]. MOVAS-1 cells were maintained in modified DMEM (ATCC #30-2002) containing 
4.5 g/L D-Glucose, 1.5 g/L sodium bicarbonate and supplemented with 10% FBS, 0.2 mg/ml G-
418, 100U/ml penicillin, and 100 µg/ml streptomycin in a 10% CO2 / 95% air humidified 
atmosphere [26]. 
Agonists used in this study were Win55,212-2,  a mixed CB1/CB2 agonist, and HU308, a 
CB2-selective agonist [27,28]. Win55,212-2 is a synthetic CB1/CB2 mixed agonist that has a 
slightly higher binding affinity for CB2 (Ki= 3.3 nM) than for CB1 (Ki= 62.3 nM). HU-308 is a 
synthetic CB2-selective agonist with a high CB2 binding affinity (Ki= 20 nM and > 10 µM for 
CB2 and CB1, respectively). Antagonists used in this experiment were SR144528, a CB2-
selective antagonist, and AM251, a CB1-selective antagonist [29,30].  AM251 is a synthetic 
cannabinoid that acts as an antagonist of CB1 (Ki= 7.5 nM).  SR144528 is a synthetic antagonist 
with a high affinity (Ki= 8.2 nM). Win55,212-2, AM251 and HU-308 were purchased from 
Cayman Chemical company (Ann Arbor MI, USA).  SR144528 was a kind gift from Sanofi-
Aventis R&D, Montpellier, France.  Unless specified, all other reagents were obtained from 
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either Fisher Scientific (Pittsburg, PA) or Sigma-Aldrich (St. Louis, MO) and were of the highest 
quality available. 
Generation of Osteoclasts from RAW264.7 Cells 
RAW264.7 is a preosteoclast cell line that undergoes RANKL-induced differentiation 
into osteoclast-like cells [26]. Raw 264.7 cells were harvested from confluent plates by scraping 
and suspended in 15 mL of culture medium. The number of cells in the suspension was 
determined using a Bright-Line Hemocytometer (Hausser Scientific, PA, USA), and 96-well 
culture plates (Corning) were seeded at a concentration of 2 × 10
3
cells/well for TRAP activity 
assay, or in 8-chambered slides for TRAP staining.  The cells were placed in a CO2 incubator 
overnight to allow the cells to attach to the surface.  After 24 h, the culture medium was replaced 
with fresh media containing 50 ng/mL RANKL (PeproTech, NJ, USA) and various CB2 agonists 
and antagonists. All compounds were added directly to culture media from sterile stock solutions 
prepared in DMSO.  Controls received an equivalent volume of the vehicle (DMSO) alone.  Two 
controls were included for each experiment.  The first contained media only and the second 
contained media supplemented with 50 ng/mL RANKL alone. The cells were then incubated for 
four days after which osteoclastogenesis was measured as follows.  
Method A: TRAP Activity Assay 
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Figure 1. Reaction Mechanism for TRAP Assay The TRAP produced by osteoclasts and 
osteoclast-like cells catalyzes a reaction where p-nitrophenyl phosphate is converted to p-
nitrophenol.  In basic conditions, p-nitrophenol loses a hydroxyl group and becomes a yellow 
compound, p-nitrophenolate, can be measured by spectrophotometry. TRAP staining uses a 
principle similar to the TRAP assay, but pNPP is soluble and will not stain cells.  Instead, 
napthol AS-B1 phosphoric acid is used. When hydrolyzed by TRAP, naphthol AS-B1 
phosphoric acid couples with a dye (Fast garnet GBC) and produces a reddish precipitate at the 
site of enzyme activity. 
TRAP activity was used to measure osteoclastogenesis by the method depicted in Figure 
1.  Briefly, the medium was aspirated and the cells were washed with 100 µL saline 
(0.9% NaCl).   The cells were then lysed with 100 µL 0.2% Triton X-100 in water (v/v) 
and incubated at room temperature for ten minutes.  Fifty microliters of the lysate from 
each well was transferred to a 96-well spectrophotometric microplate.  Substrate solution 
(50 µL) made up of 0.1M HEPES (pH 5.2) containing 50 mM Na-tartrate (an inhibitor of 
non-tartrate resistant acid phosphatase) and 4.8 mg/mL p-nitrophenyl phosphate (pNPP) 
was added to each well.  Blank wells were made by combining 50 µL of lysis solution 
with 50 µL of substrate solution.  The plate was incubated at 37°C with gentle shaking 
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for 30 to 60 minutes. Fifty microliters of stop solution (0.5 M NaOH) was added to each 
well to stop the reaction and produce the yellow p-nitrophenolate.  The intensity of the 
yellow color, and therefore TRAP activity, was measured using a SpectraMax microplate 
reader set at 405 nm (Molecular Devices).  The protein concentration of the lysates was 
determined by performing a micro-BCA assay according to the manufacturer’s 
instructions (Pierce, Rockford, IL) for the purposes of normalizing TRAP activity. The 
TRAP activity was calculated as the A405/mg protein for each sample and presented as the 
mean ±SD of quadruplicate treatments or as the fold induction of TRAP activity 
compared to the mean of untreated controls. 
Method B: TRAP Staining 
Osteoclast activity in cultured cells was visualized by TRAP staining using a 
Leukocyte Acid Phosphatase TRAP Kit from Sigma-Aldrich (St. Louis, MO, USA).  The 
staining was performed according to manufacturer’s instructions and osteoclasts were 
visualized by light microscopy using an Olympus BX41 equipped with a CCD digital 
camera. Osteoclasts were defined as TRAP-positive cells with three or more nuclei.  The 
numbers of osteoclasts in four random microscopic fields (20X magnification) were 
quantified and the data presented as the mean ±SD for each condition. 
Generation of Osteoblasts from MOVAS-1 Cells 
 MOVAS-1 cells were seeded at 10,000 cells per well in12-well plates in standard growth 
media.  After one day of incubation, the standard media was replaced with osteogenic media 
(standard media supplemented with 50 µg/mL L-ascorbic acid and 2.5 mM β-glycerophosphate) 
or osteogenic media supplemented with the desired concentration of CB2 agonists and 
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antagonists. Cells were incubated for 21-28 days with the media changed every second or third 
day before they were screened for osteoblastogenesis. Osteoblastogenesis was determined 
through two methods. 
Method A: Alkaline Phosphatase (ALP) Activity Assay 
ALP activity of osteoblasts and committed precursors was measured using a method 
similar to that used to measure TRAP activity in osteoclastogenesis.  Cells were rinsed 
three times with saline and then lysed using 0.2% TritonX-100. The mixture was clarified 
of cellular debris by centrifugation at 12,000 x g for 15 min at 4°C.  Ten microliters of 
supernatant from each sample was placed in a well of a 96-well spectrophotometric plate 
reader plate containing 40 µL of lysis buffer.  Fifty µL of substrate solution (0.2 M Tris-
HCl, pH 9.5, 1 mM MgCl2 and 4.8 mg/mL pNPP) was added to each well followed by 
incubation for 30 min at 37°C.  Blanks were made using 50 µL of lysis buffer and 50 µL 
of substrate solution. The reaction was stopped by the addition of 50 µL of stop solution 
(0.5M NaOH) and the plates were read using a spectrophotometer at 405 nm.  The 
protein concentration of the lysate was determined using a microBCA protein assay as 
described above.  ALP activity was calculated as the A405/mg protein for each sample and 
presented as the mean ±SD of triplicate treatments or as fold-induction compared to the 
mean of untreated controls. 
Method B: Alizarin red staining for calcium deposition.  
Calcification of MOVAS-1 cells was determined by Alizarin red staining as described by 
Byon et. al [21]. Briefly, the cell monolayers were rinsed with PBS and fixed with 4% 
paraformaldehyde for 5 min at 4°C.  The cells were then stained with 2% Alizarin red 
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(pH 4.2) for 5 min at room temperature.  After rinsing 5 times with distilled water and 
digitally photographed the alizarin red was extracted with 10% cetylpyridinium chloride 
for 10 minutes and the absorbance at 562 nm was determined using a microplate reading 
spectrophotometer.  The protein concentration was measured by micro-BCA assay as 
described above and the data represented as A562/mg protein. 
 14
Results 
Role of CB2 in Osteoclastogenesis 
 It was found that treatment of RAW264.7 cells with CB2 agonists reduced TRAP activity 
and the number of multi-nucleate TRAP-positive cells in culture.  Co-treatment of cells with a 
CB2 antagonist countered the inhibitory effects of agonists, indicating that CB2 signaling has an 
inhibitory effect on osteoclastogenesis of RAW264.7 cells. 
 
Figure 2. CB2 agonists inhibit RANKL-stimulated tartrate-resistant acid phosphatase 
activity (TRAP) in RAW264.7 cells. RAW264.7 cells were cultured in media containing 
RANKL and increasing amounts of a nonselective CB1/CB2 agonist, Win55,212-2 (Panel A), or 
a CB2-selective agonist, HU-308 (Panel B) as indicated. After 4 days, osteoclastogenesis was 
evaluated by assaying TRAP activity, a marker osteoclast enzyme. Data are means ± SD from 
quadruplicate determinations. * indicates p<0.05 compared to cells treated with RANKL alone. 
RAW264.7 cells undergo osteoclastogenesis when stimulated with RANKL [26]. To evaluate the 
effect of CB2 signaling on osteoclastogenesis, RAW264.7 cells were incubated in the presence 
of RANKL and various CB1/CB2 agonists.  TRAP activity in RAW264.7 cells increased 
dramatically (~7.5 fold compared to untreated controls) when stimulated with RANKL (Figure 
2).  In comparison, cells co-treated with Win55,212-2, a CB1/CB2 mixed agonist showed a dose-
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dependent and significant reduction in RANKL-stimulated TRAP activity (Figure 2a).  RANKL-
induced TRAP activity was also dose-dependently and significantly decreased in RAW264.7 
cells by co-treatment with HU-308, a CB2-selective agonist (Figure 2b).  These results suggest 
that CB2 signaling decreases osteoclastogenesis in RAW264.7 cells. 
 
Figure 3. RANKL-induced formation of TRAP positive osteoclast-like cells is reduced by 
Win55,212-2. RAW264.7 cells were cultured on multi-chambered slides in media alone 
(control) or media containing RANKL (50 ng/ml) in the absence or presence of Win55,212-2 (5 
µM), as indicated.  After 5 days, the cells were fixed and stained for TRAP. Panel A shows 
representative photomicrographs for each treatment. Arrows indicate TRAP-positive 
multinucleated cells. Panel B depicts quantitation of the number of TRAP-positive 
multinucleated cells in four random microscopic fields (40X) for each treatment.  Data are means 
± SD.  * indicates p<0.05 compared to cells treated with RANKL alone. 
 We next sought to confirm the TRAP assay results by visual quantitation of osteoclast-
like cells (TRAP-positive, multi-nucleate) within cultures of RANKL-stimulated RAW264.7 
cells treated with and without Win55,212-2.  Cells were incubated for five days in media alone, 
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media containing RANKL, or media with RANKL plus 5 µM Win5,212-2, stained for TRAP, 
and examined by light microscopy (Figure 3).  After TRAP staining, microscopic observation 
revealed the presence of large, multi-nucleated TRAP+ cells in RAW264.7 cultures treated with 
RANKL (Figure 3a). Cultures co-treated with RANKL and Win55,212-2 showed a significant 
decrease in the number of osteoclasts per microscopic field compared to cells treated with 
RANKL alone (Figure 3a). Visual quantitation of osteoclasts in four random microscopic fields 
for each treatment revealed that RANKL treatment resulted in an approximate four-fold increase 
(5.0 ± 3.5 versus 19.0 ± 7.9, p≤0.05) in the mean number of osteoclast-like cells compared to 
untreated controls.  Co-treatment with RANKL and Win55,212-2 significantly reduced the 
number of osteoclast-like cells compared to treatment with RANKL alone (9.0 ± 4.1 versus 19.0 
± 7.9, p≤0.05) (Figure 3b). 
 
Figure 4.  Inhibition of RANKL-induced TRAP activity by Win55,212-2 is sensitive to CB2-
selective antagonism. RAW264.7 cells were cultured in media containing RANKL and 
Win55,212-2 alone or in the presence of SR144524, a CB2-selective antagonist, or AM251, a 
CB1-selective antagonist, as indicated. After 4 days, osteoclastogenesis was evaluated by 
assaying TRAP activity. Data are means ± SD from quadruplicate determinations. * indicates 
P<0.05 compared to cells treated with RANKL alone. 
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 Since Win55,212-2 is a mixed CB1/CB2 agonist, we next sought to determine if the 
observed repression of RANKL-induced osteoclastogenesis in RAW264.7 by Win55,212-2 was 
mediated by CB1 or CB2.  RAW264.7 cells were treated with RANKL for four days in the 
presence of Win55,212-2 alone or in combination with AM251, a CB1-selective antagonist, or 
with SR144528, a CB2-selective antagonist [30, 29]. Co-treatment with RANKL and 
Win55,212-2 (1 µM and 5 µM) significantly reduced TRAP activity compared to cells treated 
with RANKL alone (Figure 4). Supplementation with SR144528 completely blocked the effect 
of Win55,212-2 on RANKL-induced TRAP activity at either dose. In contrast, co-treatment with 
AM251 had no effect on the ability of Win55,212-2 to repress RANKL-induced TRAP activity.  
This result indicates that the pathway by which Win55,212-2 inhibits osteoclastogenesis is 
sensitive to CB2-selective antagonism, but not CB1-selective antagonism, and therefore is likely 
mediated by CB2 activation. 
Role of CB2 in Osteoblastogenesis 
 Treatment of MOVAS-1 cells with CB2 agonists was found to increase ALP activity and 
calcium deposition in vitro.  Co-treatment of cells with CB2 antagonists reduced both ALP and 
calcium deposition relative to agonists alone, indicating that CB2 signaling encourages 
osteoblastogenesis of MOVAS-1 cells. 
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Figure 5.  Win55,212-2 dose-dependently increases the activity of ALP, an osteoblast 
marker enzyme, in MOVAS-1 cells by a mechanism sensitive to CB2 antagonism.  
MOVAS-1 cells were cultured in control media and osteogenic media (2.5 mM β-
glycerophosphate and 50 µg/ml ascorbic acid) containing increasing concentrations of 
Win55,212-2 (Panel A), and in osteogenic media containing Win55,212-2 alone or in the 
presence of a CB1 antagonist (AM251) or a CB2 antagonist (SR144528) as indicated (Panel B).  
After 21 days, osteoblastogenesis was evaluated by assaying ALP activity.  Data are means ± SD 
of triplicate determinations for Panel A and means of duplicate samples for Panel B. * indicates 
p<0.05 compared to control.  
 Previous studies indicate that CB2 signaling encourages osteoblastogenesis by promoting 
expression of osteogenic genes in precursor cells [31].   MOVAS-1 cells are a murine vascular 
smooth muscle cell line capable of spontaneous differentiation into osteoblast-like cells when 
cultured in media containing β-glycerophosphate and ascorbic acid [32].  Osteoblastogenesis was 
evaluated by measuring the induction of an osteoblast marker enzyme, alkaline phosphatase 
(ALP). As shown in figure 5, culturing MOVAS-1 cells for 21 days in osteogenic media 
supplemented with increasing concentrations of Win55,212-2 resulted in a dose dependent 
increase in ALP activity compared to MOVAS-1 cells cultured in standard media. To determine 
if CB2 played a role in Win55,212-2 enhancement of ALP activity in MOVAS-1 cells we also 
cultured cells in osteogenic media containing Win55,212-2 and either AM251 or SR144528 
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(Figure 5b).  Co-treatment with the CB2-selective antagonist SR144528 reduced ALP activity in 
Win55,212-2 treated cultures to that of untreated controls.  In contrast, ALP activity in MOVAS-
1 cells co-treated with the CB1 antagonist AM251 was similar to or greater than MOVAS-1 cells 
treated with Win55,212-2 alone (Figure 5b). Similar results were obtained when MOVAS-1 cells 
were cultured in osteogenic media containing another synthetic CB2-selective agonist, HU-308,  
or an endocannabinoid, 2-arachidonyl glycerol (data not shown). These results indicate that CB2 
signaling up-regulates osteoblastogenesis in MOVAS-1 cells by a CB2-dependent mechanism.  
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Figure 6. Win55,212-2 induces osteoblast-like cell activity in MOVAS-1 cells. MOVAS-1 
cells were cultured on 35 mm plates in standard and osteogenic media supplemented with a 
mixed CB1/CB2 agonist, Win55,212-2, as indicated.  After 21 days, the osteoblast-like cell  
activity was evaluated by staining for calcium deposition with Alizarin red-S  (Panel A).  
Photomicrographs (40X) of representative nodules of mineralization following Alizarin red 
staining are shown in Panel B.   After photography, bound Alizarin red-S was eluted with 10% 
cetylpyridinium chloride and quantified by measuring absorbance at 562 nm (Panel C).  Data are 
means ± SD. * indicates P<0.05 compared to cells untreated controls. 
 In order to confirm osteoblast-like activity in Win55,212-2-treated MOVAS-1 cultures 
we stained for calcium deposition with Alizarin red. Alizarin red staining in MOVAS-1 cells 
cultured under standard (non-calcifying) conditions was negligible in the absence or presence of 
Win55,212-2 (Figure 6). In contrast, Alizarin red staining visibly increased in a dose-dependent 
manner with Win55,212-2 treatment in  MOVAS-1 cells grown in osteogenic media (Figure 6a).  
Spectrophotometric quantitation of Alizarin red stain extracted with 10% cetylpyridinium 
confirmed that Alizarin red staining increased significantly in MOVAS-1 cells cultured in 
osteogenic media supplemented with Win55,212-2 compared to cells cultured in osteogenic 
media alone (Figure 6c). These results show that the addition of Win55,212-2 increased calcium 
deposition above that observed in untreated cells confirming the induction of an osteoblast-like 
cell activity.  
 To determine if Win55,212-2 enhanced osteoblast-like activity was due to CB2 
activation, the effect of CB2-selective antagonism on Win55,212-2 induced Alizarin red staining 
was also examined.  MOVAS-1 cells co-cultured for 21 days in osteogenic media containing 
Win55,212-2 and SR144528 (a CB2-selective antagonist), showed a notable decrease in Alizarin 
red staining compared to cells cultured with Win55,212-2 alone (Figure 7).  Furthermore, 
treatment of MOVAS-1 cells in osteogenic media with HU-308, a CB2-selective agonist, also 
enhanced Alizarin red staining (data not shown). 
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Figure 7. Win55,212-2 stimulated osteoblast-like cell activity in MOVAS-1 cells is inhibited 
by CB2 antagonism.  MOVAS-1 cells were cultured on 35 mm dishes in osteogenic media 
supplemented with Win55,212-2 (5 µM) in the presence and absence of SR144528 as indicated.  
After 21 days, osteoblast-like activity was evaluated by Alizarin red staining for calcium 
deposition.  Arrows indicate representative examples of Alizarin-stained nodules of 
mineralization. 
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Discussion 
 Atherosclerosis is a vascular disease that presents serious health risks to many people in 
Western countries.  Roughly 35.3% of Americans (36.7 % of men and 34% of women) suffer 
from some form of vascular disease. Atherosclerosis is the underlying cause of the majority of 
clinical cardiovascular events, and has no known cure [33]. It is a slow progressive disease that 
may start as early as childhood and can cause severe health issues in adults beginning in their 
thirties and becoming increasingly likely in their fifties and sixties [34]. Current treatments are 
only able to slow lesion growth by controlling clinically relevant risk factors such as blood LDL 
levels, obesity and diabetes.  However, there are currently no treatment options for the 
calcification that takes place in advanced lesions partly because the mechanisms for this lesion 
calcification as well as reasons for its occurrence are not well understood.  The goal of this 
project was to better understand the causes of lesion calcification, especially the effects of CB2 
activation on this process.  The data from this investigation supports our hypothesis that CB2 
signaling influences lesion calcification by affecting osteogenic processes in lesions to reduce 
osteoclastogenesis and activate osteoblastogenesis, thus promoting lesion calcification. 
 We observed that osteoclastogenesis was inhibited by CB2 signaling in RAW264.7 cells 
in vitro.  When cells were treated with both Win55,212-2 (a synthetic CB1/CB2 non-selective 
agonist) and HU-308 (a synthetic CB2-selective agonist), there was a significant dose-dependent 
decrease in RANKL-induced osteoclastogenesis (Figures 2 and 3).  This indicates that CB2 
signaling performs an inhibitory role in osteoclast formation.  This conclusion is supported by 
the fact that Win55,212-2 inhibition of osteoclastogenesis is sensitive to CB2 antagonism (Figure 
4).  TRAP staining verified these results.  Treatment of RAW264.7 cells with Win55,212-2 
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caused a significant decrease in osteoclastogenesis when compared to cells treated with RANKL 
alone (Figure 3). 
 In contrast, CB2 signaling was found to promote osteoblastogenesis of MOVAS-1 cells 
in vitro. When MOVAS-1 cells were treated with Win55,212-2 a significant and dose-dependent 
increase in osteoblastogenesis, as determined by ALP induction and calcium deposition, resulted 
(Figures 5 and 6).  The pathway by which promotion of osteoblastogenesis occurred was 
completely inhibited by CB2 antagonism, indicating that it was the CB2 and not the CB1 
receptor involved in promoting osteoblastogenesis (Figures 5 and 7).  There is a possibility that 
CB1 signaling may play a role in increasing osteoblastogenesis, as ALP activity of MOVAS-1 
cells increased when cells were co-treated with Win55,212-2 and CB1-selective antagonist 
AM251 (Figure 5b). However, further investigation is necessary before any conclusive results 
regarding the involvement of CB1 in osteoblastogenesis of MOVAS-1 cells.  
 Together, our results show that CB2 signaling promotes osteoblastogenesis and inhibits 
osteoclastogenesis in murine vascular precursor cells in vitro. These results indicate that 
activation of CB2 signaling within lesions could alter osteogenic processes and promote 
calcification of atherosclerotic lesions.  These results also underscore the need for future in vivo 
analysis of CB2 signaling in murine models of atherosclerosis. Confirmation of a role for CB2 in 
lesion calcification would be a potentially major discovery in atherosclerotic research and help 
clarify the little-understood phenomenon of advanced lesion calcification.  Drugs that target CB2 
receptors may have a potential for use in treatment of advanced calcified lesions, however, 
further research is necessary to understand the local and systemic effects of pharmacologically 
targeting CB2 signaling.  Both bone density and immunosuppression have been shown to be 
greatly affected by CB2 signaling [32, 14, 17], so treatments designed to target CB2 receptors in 
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lesions could potentially adversely affect patients in other areas.  Despite the potential problems, 
a better understanding of the mechanisms of lesion calcification could improve current 
treatments and potentially provide new targets for treatments. 
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